# Pan American Health Organization 

Regional Office of the
World Health Organization

## Elimination of measles and rubella in the Americas

## Measles

- Globally measles remains a leading cause of death in young children, claiming an estimated 380 lives every day, or 15 every hour (WHO data, 2010)
- In 2002, the Americas became the first WHO region to interrupt endemic measles transmission
- Between 2003 and 2010, annual notified measles cases averaged 156 per year, virtually all imported or related to importations
- In 2011, the number of measles cases in the region jumped to 1,324, due to importation of viruses from several large outbreaks occurring in Europe and Africa
- 93 percent of all cases in the Americas in 2011 were reported from three countries: Canada, Ecuador and the United States


## Rubella and CRS

- Between 1998 and 2006, the number of confirmed rubella cases in the Americas declined by 98 percentfrom 135,947 to 3,005
- In 2007, the region saw a resurgence of cases-13,187 in three countries-due to importations of rubella virus into countries that had targeted only females during mass vaccination campaigns
- In 2008-2009, 27 cases of congenital rubella syndrome (CRS) were reported in two countries: Argentina (13) and Brazil (14)
- In response to these outbreaks, countries intensified surveillance and carried out supplementary immunization activities among adolescents and adults
- The last confirmed cases of endemic rubella and CRS were reported in 2009
- Since 2009, between 7 and 15 importation-associated cases have been reported each year in the region


## Key actions

To prevent the re-introduction of endemic measles and rubella, PAHO is working with member countries to maintain high immunization coverage against measles and rubella ( $\geq 95 \%$ ) as well as high-quality surveillance to ensure effective response to any virus importations. Key recommended actions include:

1. Implement immediate vaccination activities in areas where monitoring finds coverage to be under $95 \%$ and implement high-quality follow-up vaccination campaigns
2. Conduct "rapid monitoring" of vaccine coverage to identify populations susceptible to measles and rubella, with a focus on high-risk populations
3. Implement external rapid assessments of surveillance systems for measles, rubella and CRS and strengthen registries of congenital anomalies
4. Conduct active case searches and review the sensitivity of surveillance in epidemiologically silent areas
5. Issue health alerts for mass-gathering events (such as the World Cup)
6. Involve the private sector in disease surveillance, with a focus on including private laboratories in the Regional Measles and Rubella Laboratory Network
7. Enhance collaboration between epidemiological and laboratory teams and improve molecular genotyping.
